New Two-Target drug enters human testing for Tough-to-Treat lung cancer

NCT ID NCT04995523

Recruiting now Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

Summary

This study is testing a new experimental drug called AZD2936 for people with advanced or metastatic non-small cell lung cancer. The main goals are to find a safe dose and see if the drug helps shrink tumors, especially in patients whose cancer has worsened after previous immunotherapy. The trial will enroll about 210 participants and is currently recruiting.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Research Site
WITHDRAWN

Orange, California, 92868, United States
Research Site
RECRUITING

Chicago, Illinois, 60637, United States
Research Site
WITHDRAWN

Baltimore, Maryland, 21201, United States
Research Site
RECRUITING

Rochester, Minnesota, 55905, United States
Research Site
WITHDRAWN

Houston, Texas, 77030, United States
Research Site
RECRUITING

Fairfax, Virginia, 22031, United States
Research Site
COMPLETED

Melbourne, 3000, Australia
Research Site
ACTIVE_NOT_RECRUITING

Anderlecht, 1070, Belgium
Research Site
ACTIVE_NOT_RECRUITING

Leuven, 3000, Belgium
Research Site
RECRUITING

Florianópolis, 88034-000, Brazil
Research Site
RECRUITING

Natal, 59075-740, Brazil
Research Site
RECRUITING

Porto Alegre, 90035903, Brazil
Research Site
RECRUITING

Rio de Janeiro, 20231-050, Brazil
Research Site
RECRUITING

São Paulo, 01246-000, Brazil
Research Site
RECRUITING

Chengdu, 610041, China
Research Site
ACTIVE_NOT_RECRUITING

Chongqing, 400030, China
Research Site
WITHDRAWN

Wuhan, 430022, China
Research Site
ACTIVE_NOT_RECRUITING

Copenhagen, 2100, Denmark
Research Site
RECRUITING

Dijon, 21079, France
Research Site
RECRUITING

Toulouse, 31059, France
Research Site
RECRUITING

Tbilisi, 0112, Georgia
Research Site
RECRUITING

Kashiwa, 227-8577, Japan
Research Site
RECRUITING

Niigata, 951-8566, Japan
Research Site
RECRUITING

Sendai, 981-0914, Japan
Research Site
RECRUITING

Tokyo, 104-0045, Japan
Research Site
RECRUITING

Kuala Lumpur, 59100, Malaysia
Research Site
RECRUITING

Kuching, 93586, Malaysia
Research Site
RECRUITING

Chisinau, MD-2025, Moldova
Research Site
ACTIVE_NOT_RECRUITING

Groningen, 9713 GZ, Netherlands
Research Site
ACTIVE_NOT_RECRUITING

Leiden, 2333 ZA, Netherlands
Research Site
COMPLETED

Utrecht, 3584 CX, Netherlands
Research Site
WITHDRAWN

Singapore, 308433, Singapore
Research Site
RECRUITING

Seoul, 03082, South Korea
Research Site
RECRUITING

Seoul, 03722, South Korea
Research Site
RECRUITING

Seoul, 05505, South Korea
Research Site
ACTIVE_NOT_RECRUITING

Barcelona, 08035, Spain
Research Site
ACTIVE_NOT_RECRUITING

Madrid, 28027, Spain
Research Site
ACTIVE_NOT_RECRUITING

Madrid, 28041, Spain
Research Site
RECRUITING

Taichung, 40201, Taiwan
Research Site
RECRUITING

Taichung, Taiwan
Research Site
RECRUITING

Tainan, 70403, Taiwan
Research Site
WITHDRAWN

Taipei, 10002, Taiwan
Research Site
RECRUITING

Taipei, 110, Taiwan
Research Site
RECRUITING

Bangkok, 10700, Thailand
Research Site
RECRUITING

Chanthaburi, 22000, Thailand
Research Site
RECRUITING

Muang, 50200, Thailand
Research Site
WITHDRAWN

Leicester, LE1 5WW, United Kingdom
Research Site
WITHDRAWN

Manchester, M20 4BX, United Kingdom

Conditions

Explore the condition pages connected to this study.

NON-SMALL CELL LUNG CARCINOMA